Associations of body composition measures with circulating insulin-like growth factor-I, testosterone, and sex hormone-binding globulin concentrations in 16,000 men.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101256108 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5497 (Electronic) Linking ISSN: 03070565 NLM ISO Abbreviation: Int J Obes (Lond) Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : Nature Pub. Group, c2005-
    • Subject Terms:
    • Abstract:
      Background: Adiposity is positively associated with risk of some cancer sites and other health conditions in men; however, it is unclear if endogenous hormones play a role in these associations. We examined how body composition, measured from magnetic resonance imaging (MRI) and common measures of adiposity (e.g., body mass index (BMI)), are related to hormone concentrations in men from the UK Biobank study.
      Methods: Up to 16,237 men with available body composition data (including visceral, subcutaneous, and liver fat, muscle fat infiltration (MFI), lean tissue, and common adiposity measures) and serum hormone measurements (insulin-like growth factor-I (IGF-I), total testosterone, sex hormone-binding globulin (SHBG), and calculated free testosterone) were included. Multivariable-adjusted linear regression models were used to determine the geometric mean hormone and SHBG concentrations across categories of each exposure.
      Results: Common measurements of adiposity were highly correlated with MRI measures of central and total adiposity (r = 0.76-0.91), although correlations with ectopic fat (liver fat and MFI) were lower (r = 0.43-0.54). Most adiposity measurements showed an inverse U- or J-shaped association with circulating IGF-I and free testosterone; however, MFI was linearly inversely associated, and lean tissue volume was positively associated with both IGF-I and free testosterone concentrations. All body composition measures were inversely associated with total testosterone and SHBG concentrations (relative geometric mean difference between Q5 vs. Q1: 20-30%).
      Conclusion: Our results show that common adiposity and most MRI measures of adiposity relate similarly to serum hormone concentrations; however, associations with ectopic fat (particularly MFI) and lean tissue were different.
      Competing Interests: Competing interests: The authors declare no competing interests. Ethical approval: The UK Biobank has received ethics approval from the North West Multi-centre Research Ethics Committee (2021 approval reference 16/NW/0274). All participants provided informed consent to participate at recruitment. Our research required no additional ethical clearance.
      (© 2024. The Author(s).)
    • References:
      BMJ. 2020 Feb 12;368:m131. (PMID: 32051121)
      Gastroenterology. 2020 Apr;158(5):1300-1312.e20. (PMID: 31884074)
      Nat Rev Cancer. 2015 Aug;15(8):484-98. (PMID: 26205341)
      Am J Clin Nutr. 2008 Jun;87(6):1959; author reply 1959-60. (PMID: 18541591)
      N Engl J Med. 2016 Aug 25;375(8):794-8. (PMID: 27557308)
      Int J Cancer. 2022 Oct 1;151(7):1033-1046. (PMID: 35579976)
      J Clin Endocrinol Metab. 2008 Jun;93(6):2334-43. (PMID: 18349062)
      BMC Gastroenterol. 2020 Jun 25;20(1):199. (PMID: 32586279)
      Sci Rep. 2022 Dec 29;12(1):22528. (PMID: 36581676)
      J Am Coll Cardiol. 2016 Feb 9;67(5):545-57. (PMID: 26846952)
      Obesity (Silver Spring). 2012 Jan;20(1):76-87. (PMID: 21660078)
      Obes Facts. 2011;4(1):9-15. (PMID: 21372606)
      J Clin Endocrinol Metab. 2018 Jun 1;103(6):2167-2174. (PMID: 29618085)
      Eur Heart J. 2021 Sep 7;42(34):3388-3403. (PMID: 34333589)
      Surg Obes Relat Dis. 2018 Apr;14(4):462-468. (PMID: 29254689)
      Med Hypotheses. 2001 Jun;56(6):702-8. (PMID: 11399122)
      Singapore Med J. 2003 Dec;44(12):614-9. (PMID: 14770254)
      J Clin Endocrinol Metab. 2007 Feb;92(2):549-55. (PMID: 17148559)
      Cancer Epidemiol Biomarkers Prev. 2002 Jun;11(6):581-6. (PMID: 12050100)
      Eur J Endocrinol. 2006 May;154(5):699-706. (PMID: 16645017)
      Eur J Endocrinol. 2011 May;164(5):811-7. (PMID: 21346095)
      Nat Commun. 2020 May 26;11(1):2624. (PMID: 32457287)
      J Clin Endocrinol Metab. 2008 Jan;93(1):139-46. (PMID: 17940111)
      Calcif Tissue Int. 2019 Sep;105(3):285-293. (PMID: 31161375)
      CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
      PLoS One. 2017 Dec 27;12(12):e0187741. (PMID: 29281666)
      Exp Clin Endocrinol Diabetes. 2012 Mar;120(3):171-4. (PMID: 22402920)
      Int J Obes (Lond). 2008 Aug;32 Suppl 3:S56-9. (PMID: 18695655)
      Diabet Med. 2004 Dec;21(12):1339-45. (PMID: 15569138)
      Growth Horm IGF Res. 2012 Jun-Aug;22(3-4):139-45. (PMID: 22591999)
      Br J Pharmacol. 2008 Jun;154(3):522-8. (PMID: 18414389)
      Ann Hepatol. 2017 May - Jun 2017;16(3):382-394. (PMID: 28425408)
      Age (Dordr). 2012 Feb;34(1):145-56. (PMID: 21347608)
      Obes Rev. 2010 Jan;11(1):11-8. (PMID: 19656312)
      Int J Impot Res. 2008 Jul-Aug;20(4):378-87. (PMID: 18480825)
      Endocr Rev. 2017 Aug 1;38(4):302-324. (PMID: 28673039)
      J Obes. 2013;2013:291546. (PMID: 24073332)
      Am J Physiol Endocrinol Metab. 2003 Jul;285(1):E197-205. (PMID: 12670837)
      Int J Cancer. 2021 May 1;148(9):2274-2288. (PMID: 33252839)
      J Transl Med. 2016 Jan 06;14:3. (PMID: 26733412)
      Am J Epidemiol. 2017 Nov 1;186(9):1026-1034. (PMID: 28641372)
      J Clin Endocrinol Metab. 2007 Jul;92(7):2696-705. (PMID: 17426100)
      Wellcome Open Res. 2020 Sep 24;5:222. (PMID: 33364437)
      Nat Rev Endocrinol. 2013 Jun;9(6):346-56. (PMID: 23568441)
      J Clin Endocrinol Metab. 2007 Feb;92(2):405-13. (PMID: 17090633)
      Maturitas. 1980 Jul;2(2):109-18. (PMID: 7193795)
      Trends Endocrinol Metab. 2015 Jul;26(7):376-83. (PMID: 26044465)
      Int J Cancer. 2019 Dec 15;145(12):3244-3256. (PMID: 30873591)
      Cancer Causes Control. 2002 Aug;13(6):509-16. (PMID: 12195640)
      Int J Epidemiol. 2023 Feb 8;52(1):71-86. (PMID: 35726641)
    • Accession Number:
      0 (Sex Hormone-Binding Globulin)
      3XMK78S47O (Testosterone)
      67763-96-6 (Insulin-Like Growth Factor I)
      0 (Insulin-Like Peptides)
    • Publication Date:
      Date Created: 20241021 Date Completed: 20241123 Latest Revision: 20241125
    • Publication Date:
      20241126
    • Accession Number:
      PMC11584381
    • Accession Number:
      10.1038/s41366-024-01633-0
    • Accession Number:
      39433891